Thrombocytopenia Associated with Apixaban Use

Clinical Approach and Guidelines

When thrombocytopenia develops in a patient taking apixaban, investigate alternative causes such as concurrent medications that affect platelet counts, underlying hematologic disorders, infection or sepsis, liver disease or cirrhosis, malignancy, and recent chemotherapy exposure, as recommended by the American Society of Clinical Oncology, based on evidence from Annals of Oncology 1
The American Society of Hematology recommends apixaban as an acceptable non-heparin anticoagulant option for heparin-induced thrombocytopenia (HIT) management, with a recommended dose of 10 mg twice daily, according to the 2018 ASH guidelines 2
In patients with cancer-associated thrombosis and thrombocytopenia, the International Society on Thrombosis and Haemostasis (ISTH) guidance suggests withholding anticoagulation in patients with platelet counts <25,000/μL who are at lower risk for recurrent VTE, as reported in Annals of Oncology 1
For patients with platelet counts >50,000/μL and no evidence of bleeding, standard-dose anticoagulation is recommended, with case-by-case decisions for platelet counts <50,000/μL, according to the American Society of Clinical Oncology, based on evidence from Annals of Oncology 1

Apixaban is a direct factor Xa inhibitor that works by blocking the coagulation cascade, not by affecting platelet production or function 3
Unlike heparin, apixaban does not interact with platelet factor 4 (PF4) or cause immune-mediated platelet destruction 4, 5
In studies of heparin-induced thrombocytopenia (HIT), apixaban has been shown to have no effect on the interactions between PF4 or PF4/heparin complexes and platelets 4

The American Society of Hematology (ASH) 2018 guidelines list apixaban as an acceptable non-heparin anticoagulant option for HIT management, with a recommended dose of 10 mg twice daily 6
The American College of Cardiology notes that apixaban has a favorable safety profile compared to warfarin, with lower rates of major bleeding complications 7

When thrombocytopenia occurs in a patient taking apixaban, alternative causes should be investigated rather than automatically attributing it to the medication 4, 5
Patients with baseline thrombocytopenia or platelet counts <50,000/mm³ were typically excluded from major clinical trials, so data in this population is limited 8

In patients treated with apixaban, thrombocytopenia occurs in < 1% of cases, which is substantially lower than the 3.5–6.3% incidence reported for glycoprotein IIb/IIIa inhibitors and the 1–13% range observed with various heparin products (rates vary by duration and type of heparin) 9, 10.